MX344302B - Compuestos de quinazolina sustituidos con alquino y metodos uso. - Google Patents

Compuestos de quinazolina sustituidos con alquino y metodos uso.

Info

Publication number
MX344302B
MX344302B MX2013010016A MX2013010016A MX344302B MX 344302 B MX344302 B MX 344302B MX 2013010016 A MX2013010016 A MX 2013010016A MX 2013010016 A MX2013010016 A MX 2013010016A MX 344302 B MX344302 B MX 344302B
Authority
MX
Mexico
Prior art keywords
methods
substituted quinazoline
alkyne substituted
quinazoline compound
compounds
Prior art date
Application number
MX2013010016A
Other languages
English (en)
Other versions
MX2013010016A (es
Inventor
Xiaoling Zheng
Wang Shen
Aimin Zhang
Jack Maung
Original Assignee
Newgen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newgen Therapeutics Inc filed Critical Newgen Therapeutics Inc
Publication of MX2013010016A publication Critical patent/MX2013010016A/es
Publication of MX344302B publication Critical patent/MX344302B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona compuestos de quinazolina sustituidos con alquino, tales como compuestos de la fórmula (I), los cuales son inhibidores de la quinasa ErbB irreversible. Los compuestos son útiles en el tratamiento de enfermedades y trastornos en donde la actividad de la quinasa ErbB está implicada como un trastorno hiperproliferativo (por ejemplo, cáncer).
MX2013010016A 2011-03-04 2012-03-02 Compuestos de quinazolina sustituidos con alquino y metodos uso. MX344302B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161449088P 2011-03-04 2011-03-04
PCT/US2012/027614 WO2012122058A2 (en) 2011-03-04 2012-03-02 Alkyne substituted quinazoline compound and methods of use

Publications (2)

Publication Number Publication Date
MX2013010016A MX2013010016A (es) 2013-11-20
MX344302B true MX344302B (es) 2016-12-13

Family

ID=46798728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010016A MX344302B (es) 2011-03-04 2012-03-02 Compuestos de quinazolina sustituidos con alquino y metodos uso.

Country Status (14)

Country Link
US (5) US9090588B2 (es)
EP (1) EP2680850B1 (es)
JP (1) JP6006242B2 (es)
KR (4) KR20210043016A (es)
CN (1) CN103998040B (es)
AU (3) AU2012225693A1 (es)
BR (1) BR112013022552B1 (es)
CA (1) CA2828713C (es)
IL (1) IL228072A (es)
MX (1) MX344302B (es)
RU (1) RU2013144571A (es)
SG (3) SG10201913982WA (es)
TW (1) TWI617556B (es)
WO (1) WO2012122058A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210043016A (ko) 2011-03-04 2021-04-20 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN102898386B (zh) * 2011-07-27 2015-07-29 上海医药集团股份有限公司 喹唑啉衍生物、其制备方法、中间体、组合物及其应用
US9556191B2 (en) 2013-04-28 2017-01-31 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
CN103254156B (zh) * 2013-05-10 2015-08-26 苏州明锐医药科技有限公司 阿法替尼中间体的制备方法
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
US10787428B2 (en) 2015-12-24 2020-09-29 Kyowa Kirin Co., Ltd. α,β-unsaturated amide compound
DE102016224889B4 (de) * 2016-12-14 2019-11-07 Airbus Defence and Space GmbH Verfahren zur Vorbeugung einer Ablösung einer Fluidströmung, Strömungskörpersystem und Luftfahrzeug
US11083492B2 (en) * 2018-06-06 2021-08-10 Lifetech Scientific (Shenzhen) Co., Ltd Method for implanting an interventional medical device
US10973321B2 (en) 2018-09-04 2021-04-13 Steelcase Inc. Workspace system and components and method for the use thereof
KR20210137422A (ko) 2018-09-25 2021-11-17 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도
KR20220047810A (ko) * 2019-08-15 2022-04-19 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 알키닐 퀴나졸린 화합물
TWI820414B (zh) * 2020-04-17 2023-11-01 大陸商北京賽特明強醫藥科技有限公司 喹唑啉類化合物、製備方法及其應用
CN113527215B (zh) * 2020-04-17 2023-12-05 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062881A (en) 1974-07-26 1977-12-13 Cincinnati Milacron Chemicals, Inc. Sulfide containing tin stabilizers
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
EP0326307B1 (en) 1988-01-23 1994-08-17 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
US5053227A (en) 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
JP3089901B2 (ja) 1993-07-20 2000-09-18 株式会社豊田自動織機製作所 クラッチレス圧縮機における動力伝達構造
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9405355D0 (en) 1994-03-18 1994-05-04 Lucas Ind Plc Vibrating element transducer
WO1996029331A1 (de) 1995-03-20 1996-09-26 Dr. Karl Thomae Gmbh Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
KR100256707B1 (ko) 1995-05-12 2000-05-15 해피 페너 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3290666B2 (ja) 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
DE69618587T2 (de) 1995-06-07 2002-08-29 Sugen, Inc. Chinazoline und pharmazeutische zusammensetzungen
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
AU2522197A (en) 1996-04-16 1997-11-07 Ube Industries, Ltd. Hydrazine compounds, process for the preparation thereof, and insecticides for agricultural and horticultural use
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU5391099A (en) 1998-07-30 2000-02-21 American Home Products Corporation Substituted quinazoline derivatives
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
AU7307101A (en) 2000-06-30 2002-01-14 Glaxo Group Ltd Quinazoline ditosylate salt compounds
IL155029A0 (en) 2000-10-27 2003-10-31 Novartis Ag Treatment of gastrointestinal stromal tumors
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7294629B2 (en) * 2001-02-21 2007-11-13 Mitsubishi Pharma Corporation Quinazoline derivatives
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
JP4353903B2 (ja) 2005-01-07 2009-10-28 東京エレクトロン株式会社 クラスタツールの処理システム
JP2008545688A (ja) * 2005-05-25 2008-12-18 ワイス 置換３−シアノキノリン並びにその中間体を合成する方法
WO2007054550A1 (en) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
CA2639936C (en) 2006-01-26 2014-06-17 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
CN100345856C (zh) 2006-03-10 2007-10-31 武汉化工学院 一种制备葡萄糖醛酸内酯的酯化及结晶工艺方法
WO2008033749A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Quinazoline based egfr inhibitors containing a zinc binding moiety
CN101646679A (zh) 2007-03-29 2010-02-10 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8735409B2 (en) 2009-12-21 2014-05-27 Qiang Zhang Quinazoline derivatives
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
KR20210043016A (ko) 2011-03-04 2021-04-20 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途

Also Published As

Publication number Publication date
US20160031860A1 (en) 2016-02-04
SG193291A1 (en) 2013-10-30
CA2828713A1 (en) 2012-09-13
BR112013022552B1 (pt) 2021-11-23
US9090588B2 (en) 2015-07-28
IL228072A0 (en) 2013-09-30
SG10201601711SA (en) 2016-04-28
KR102061743B1 (ko) 2020-01-03
WO2012122058A3 (en) 2014-04-24
US20210047303A1 (en) 2021-02-18
EP2680850A4 (en) 2015-01-28
US20180093975A1 (en) 2018-04-05
MX2013010016A (es) 2013-11-20
KR20200003933A (ko) 2020-01-10
AU2018267622A1 (en) 2018-12-13
US11524956B2 (en) 2022-12-13
CA2828713C (en) 2022-08-16
AU2018267622B2 (en) 2020-05-14
AU2017200984A1 (en) 2017-03-02
CN103998040A (zh) 2014-08-20
US20190382382A1 (en) 2019-12-19
JP2014518544A (ja) 2014-07-31
KR20140020955A (ko) 2014-02-19
BR112013022552A2 (pt) 2016-12-06
RU2013144571A (ru) 2015-04-10
JP6006242B2 (ja) 2016-10-12
TW201249835A (en) 2012-12-16
IL228072A (en) 2016-08-31
US20140128417A1 (en) 2014-05-08
CN103998040B (zh) 2017-03-29
AU2012225693A1 (en) 2013-09-19
SG10201913982WA (en) 2020-03-30
KR20220031732A (ko) 2022-03-11
EP2680850A2 (en) 2014-01-08
TWI617556B (zh) 2018-03-11
EP2680850B1 (en) 2018-05-23
KR20210043016A (ko) 2021-04-20
WO2012122058A2 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
MX344302B (es) Compuestos de quinazolina sustituidos con alquino y metodos uso.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX362550B (es) Inhibidores ciclicos de glutaminasa.
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
BR112015000399A2 (pt) derivados de pirazolil pirimidina
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
IN2014MN02082A (es)
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
MX355088B (es) Inhibidores de tienopirimidina de proteina cinasa c atipica.
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
PH12016500735A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
MX353062B (es) Nuevas carboxamidas heterociclicas como moduladores de la activadad de cinasas.

Legal Events

Date Code Title Description
FG Grant or registration